Drugs / Stem Cell Educator
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04011748 | Sep 2022 → Jul 2023 | alopecia areata, alopecia totalis, alopecia universalis | Throne Biotechnologies Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-08-06 | Throne Biotechnologies Inc. | Results Successfully treat a Patient with Long-Standing Crohn’s Disease with Stem Cell Educator Therapy thronebio.com ↗
After the treatment with Stem Cell Educator therapy, patient’s clinical symptoms were quickly improved with normal bowel movements, without abdominal pain or rectal bleeding. |
| 2024-07-30 | Throne Biotechnologies Inc. | Results New Publication: Increase in the Expression of Glucose Transporter 2 on the Peripheral Blood Insulin-Producing Cells in Type 1 Diabetic Patients After Receiving Stem Cell Educator Therapy thronebio.com ↗
After the treatment with Stem Cell Educator therapy, the percentages of GLUT2+CD45RO+ PB-IPC were markedly increased in these T1D subjects. |
| 2024-04-28 | Throne Biotechnologies Inc. | Regulatory Throne Received FDA Approval on Regenerative Medicine Advanced Therapy (RMAT) Designation by Using Stem Cell Educator Therapy to Treat Type 1 Diabetes thronebio.com ↗
We are excited to announce that Throne achieved the FDA approval on the Regenerative Medicine Advanced Therapy (RMAT) designation by using Stem Cell Educator therapy to treat type 1 diabetes. |
| 2024-02-05 | Throne Biotechnologies Inc. | Results New Studies Revealed the New Molecular Mechanisms Underlying Stem Cell Educator Therapy on Human B Cells thronebio.com ↗
The current study revealed that CB-SC directly displayed multiple immune modulations on B-cell proliferation and differentiation and antibody productions through the Galectin-9-mediated mechanism and calcium flux/Akt/Erk1/2 signaling pathways. |
| 2022-03-14 | Throne Biotechnologies Inc. | Results Why Can Stem Cell Educator Therapy Be Utilized to Treat Type 2 Diabetes? thronebio.com ↗
To determine the clinical efficacy of Stem Cell Educator therapy in T2D, Dr. Zhao and colleagues found that about 70% of T2D patients achieved the improved metabolic control, with marked reduction of median glycated hemoglobin (HbA1 C) values |
| 2021-10-11 | Throne Biotechnologies Inc. | Results New Molecular Mechanism for Stem Cell Educator Therapy: Suppression of B-Cell Activation by Cord Blood-Derived Stem Cells (CB-SC) via Galectin-9-Dependent Cell Contact Mechanism thronebio.com ↗
Recently, Dr. Yong Zhao and his team demonstrated the CB-SC-induced immunomodulation on activated B cells by inhibiting the B-cell proliferation and the activation of naïve B cells, down-regulating the differentiation of switched memory B cells, and reducing the production of immunoglobulins. |
All press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stem Cell Educator | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04011748 ↗ |
| Known as | SCE | “Stem Cell Educator (SCE) therapy, which uses only autologous mononuclear cells that are externally exposed to cord blood stem cells, has previously been proven safe and...” NCT04011748 ↗ |
| Modality | Cell therapy | “a Stem Cell Educator therapy in which a patient's blood is circulated through a closed-loop system that separates mononuclear cells from the whole blood, allows the cells to...” PMID 25896390 ↗ Apr 2015 |